Nkarta, Inc. (NKTX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$30.1M
Cash & Equivalents
$28.2M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$212M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase1 Readout | — |
| 2027-04-01 | Phase2 Readout | — |
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06557265 | A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) | PHASE2 | Recruiting | 120 |
| NCT06733935 | A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) | PHASE2 | Recruiting | 240 |
| NCT04623944 | NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS | PHASE1 | Active Not Recruiting | 61 |
| NCT05020678 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | PHASE1 | Active Not Recruiting | 150 |
| NCT06518668 | A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus | PHASE1 | Enrolling By Invitation | 6 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.